Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
16 April 2021Website:
http://www.akoyabio.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 29 Oct 2024 20:01:58 GMTDividend
Analysts recommendations
Institutional Ownership
AKYA Latest News
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust
MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya's board. Mr. Mendel has served as a member of Akoya's board of directors since June 2021 and has over 30 years of financial and operational management experience.
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.27 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.51 per share a year ago.
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses.
Akoya Biosciences, Inc. (NASDAQ: AKYA) Q1 2024 Earnings Conference Call on May 13, 2024 at 5:00 PM ET with Company Participants Priyam Shah, Brian McKelligon, and Johnny Ek, as well as various Conference Call Participants. Thank you for joining the Akoya Biosciences First Quarter 2024 Earnings Conference Call.
Akoya Biosciences (AKYA) reported a quarterly loss of $0.35 per share, which was higher than the expected loss of $0.30 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.49 per share reported in the same quarter last year.
Akoya (AKYA) lacks the necessary elements for a potential earnings surprise in its upcoming report. Be ready with the key projections.
Akoya Biosciences, Inc. (NASDAQ:AKYA ) Q4 2023 Earnings Conference Call March 4, 2024 5:00 PM ET Company Participants Priyam Shah - Head, IR Brian McKelligon - CEO Johnny Ek - CFO Conference Call Participants Subbu Nambi - Guggenheim Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley John Sourbeer - UBS Mark Massaro - BTIG Rachel Vatnsdal - JP Morgan Operator Good day and thank you for standing by. Welcome to the Akoya Biosciences Fourth Quarter 2023 Earnings Conference Call.
Akoya Biosciences (AKYA) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.50 per share a year ago.
- 1(current)
What type of business is Akoya Biosciences?
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
What sector is Akoya Biosciences in?
Akoya Biosciences is in the Healthcare sector
What industry is Akoya Biosciences in?
Akoya Biosciences is in the Medical Instruments & Supplies industry
What country is Akoya Biosciences from?
Akoya Biosciences is headquartered in United States
When did Akoya Biosciences go public?
Akoya Biosciences initial public offering (IPO) was on 16 April 2021
What is Akoya Biosciences website?
https://www.akoyabio.com
Is Akoya Biosciences in the S&P 500?
No, Akoya Biosciences is not included in the S&P 500 index
Is Akoya Biosciences in the NASDAQ 100?
No, Akoya Biosciences is not included in the NASDAQ 100 index
Is Akoya Biosciences in the Dow Jones?
No, Akoya Biosciences is not included in the Dow Jones index
When was Akoya Biosciences the previous earnings report?
No data
When does Akoya Biosciences earnings report?
The next expected earnings date for Akoya Biosciences is 08 November 2024